Amparo de la Peña is the VP of Pharmacometrics at Simulations Plus (SLP), Clinical Pharmacology and Pharmacometrics Business Unit. She earned her Bachelor of Chemistry and Pharmaceutical Chemist degrees from the University of the Republic, Uruguay, and a Ph.D. in Pharmaceutics from the University of Florida, under Dr. Hartmut Derendorf.
Over the following 21 years, she accrued experience in the pharmaceutical industry at Eli Lilly and Company, both as a PK/PD scientist and as an Asset Manager. Amparo also has more than 10 years of consulting experience, starting at Chorus (Lilly) and now at SLP. Through those years, she led cross-functional teams in diverse therapeutic areas (e.g. diabetes, neuroscience, oncology, rare diseases, and COVID-19) to design, optimize, and implement integrated development plans. As a scientist, she has guided strategic pharmacometrics approaches to support global drug development from the early stages to regulatory approval and post-marketing.
During her career, she has been a member of scientific organizations such as ISOP, ACCP, ASCPT, and AAPS, and has volunteered for them as an abstract reviewer (AAPS), coordinating student awards (AAPS), by volunteering in committees, providing ideas for highlighting members and developing presentations to educate about the organization (ACCP), by submitting abstracts (PAGE) and organizing workshop proposals, teaching a workshop (ACoP) or chairing a symposium (ACoP, AAPS), and by reviewing manuscripts for peer-reviewed journals. She has also held memberships and given scientific presentations for therapeutic area organizations (e.g. ADA, EASD, ICAAC, ECCMID, and ISSX).
She has published extensively in peer-reviewed journals in several languages, and presented at scientific conferences worldwide. One of her passions is to mentor and develop diverse people, and to foster inclusion. Besides work, her time is shared between my family and her involvement in scientific and community organizations as a volunteer, peer reviewer, or Board member.